Director, Nonclinical Due Diligence & External Innovation

Responsibilities

• Leads operational execution of nonclinical due diligence for assigned opportunities.
• Acts as hands-on scientific integrator, translating expert input into clear risk narratives.
• Trusted subject-matter lead for nonclinical DD on individual deals.
• Lead end-to-end nonclinical due diligence for individual assets or transactions, from request through final governance readout.
• Integrate input from Toxicology, PK/QSP, Nonclinical Pharmacology, and external experts into a single, coherent scientific assessment.
• Identify FIH-enabling gaps, translational risks, and regulatory limitations, with clear mitigation proposals.
• Prepare high-quality DD reports, executive summaries, and risk tables for governance review.
• Act as NCD scientific interface to Business Development and Therapeutic Area teams at the project level.
• Contribute to maintenance and continuous improvement of nonclinical DD frameworks and templates.
• Mentor junior contributors and matrix team members as appropriate.
• Escalates complex or high-impact issues to Head of NCD
• Chair of “NCD Review Committee”

Qualifications

• Advanced degree (Ph.D., D.V.M., or equivalent) in toxicology, pharmacology, or a related field.
• Toxicology training, board certification preferred.
• Experience in nonclinical development (10+ years) with proven experience in due diligence or external innovation, ideally across various geographies.
• Strong understanding of FIH-enabling nonclinical requirements, particularly for biologics and complex modalities.
• Ability to communicate complex scientific risk clearly to non-expert stakeholders.
• Experience across multiple therapeutic areas and modalities is highly desirable.